Delving into the Latest Updates on MAPS Europe B.V. with Synapse

Overview

Tags

Nervous System Diseases

Digestive System Disorders

Other Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

5-HT2A receptor x SERT	1

The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people diagnosed with at least severe PTSD.
The main question it aims to answer is: Do two open-label sessions of MDMA-assisted therapy reduce PTSD symptoms?
Participants will receive three non-drug preparatory sessions followed by two sessions of MDMA-assisted therapy. Each MDMA-assisted therapy session is followed by three non-drug integrative therapy sessions.

Start Date24 Jun 2020

Sponsor / Collaborator

MAPS Europe B.V.

[+1]

100 Clinical Results associated with MAPS Europe B.V.

Login to view more data

0 Patents (Medical) associated with MAPS Europe B.V.

Login to view more data

100 Deals associated with MAPS Europe B.V.

Login to view more data

100 Translational Medicine associated with MAPS Europe B.V.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Login to view more data